Welcome to 2021. It’s the first ILCA Newsletter of the year – a year which we hope will feature more highs and fewer lows than the last one! Here’s a snapshot of what’s coming up in this newsletter:
  • Updates from the President
  • Latest News in Liver Cancer Science
  • Best of ILCA 2020 Webinar
  • ILCA Annual Conference #ILCA21
  • Membership
  • Related Organisations


Message from the President

Prof. Bruno Sangro, MD, PhD
Director of the Liver Unit at Clínica Universidad de Navarra
ILCA President

Dear colleagues,

Happy New Year! 2021 has come full of hope. The most relevant is hope that vaccination will help us deal with the COVID-19 pandemic in a more efficient way. Yet, we all understand that the challenges will persist and therefore we will have to persevere in our aim to succeed in ILCA mission against current problems. As an ILCA member there are many different ways you can help in such endeavor. If you have ideas about new initiatives or would like to participate actively in the current activities and leadership bodies, please contact myself or any Executive Committee members.

As we work hard in planning our Annual Conference, please pay attention to activities that will take place in the first semester. A Best of ILCA Webinar will be delivering updated information for those in Eastern countries that found it difficult to attend the livestreamed presentations in our last Annual Conference because of differences in time zones. A Single Topic Workshop will address the important issue of biomarkers for liver cancer. And a new ILCA School of Liver Cancer will be running in Aarhus, Denmark. A new members platform is being developed and will be launched soon, and other news will shortly follow.

With Coronavirus still disrupting our daily life and causing much suffering and pain, I would like to remain close to you and wish you the best for this coming year.

Bruno Sangro
Director of the Liver Unit at Clínica Universidad de Navarra
ILCA President


Latest News in Liver Cancer Science

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma

Single-cell RNA-seq enables to exquisitely characterize healthy and diseased tissues. Several studies have performed scRNA-seq of primary HCC tumors. However, in this study, the profiling has been conducted on recurrent lesions. Compared to primary HCCs, the immune landscape in early relapsed tumors was significantly different, with a reduction in Treg and an increase in dendritic cells and CD8 T cells. Interestingly, malignant cells in early relapse presented features of immune evasion, which can affect the unique immune landscape.

(Sun, Yunfan et al. Cell, 21 January 2021)

A novel waitlist dropout score for hepatocellular carcinoma – identifying a threshold that predicts worse post-transplant survival

This study identified a score combining size and numbers of tumors, AFP, the increase of MELD-Na and Child-Pugh scores that predicts drop out on the waiting list for transplantation for HCC in a cohort of 2092 patients. This score was validated in two cohorts of 1735 and 2894 patients. A score < 7 was associated with a one-year drop out of 7.1% and a score > 23 to a one-year drop out of 39.5%. This score was also predictive of death after transplantation.

(Mehta, Neil et al. European Association for the Study of the Liver, 11 November 2020)


Best of ILCA 2020 Webinar

Thursday, 25th February 2021
7am EST | 1pm CET | 8pm SGT

Mark you calendar for the webinar Best of ILCA 2020. Join us to learn the latest in clinical practice and research in liver cancer.


ILCA Annual Conference #ILCA21

At ILCA 2021, you can expect a week of cutting-edge ideas and upskilling opportunities to drive patient care and to impact careers. You can get inspired with practical insights, workshops, big idea presentations and, of course, exciting formats to encourage knowledge sharing and networking between physicians, researchers, and partners from all over the world.

The scientific programme will offer to participants with a large variety of different sessions dedicated to better prevent and treat liver cancer. Scientific and medical experts from around the world will exchange the latest scientific advances and best practices in liver cancer research and care. A world-level scientific programme is lined up for you again this year.

Visit the ILCA 2021 Website

Call for Abstracts Now Open

Submit your abstract and be part of ILCA 2021! We need your latest research to shape this year’s content. Share your expertise with the global liver cancer community.

Abstracts should address all aspects of liver cancer with a clear emphasis on maximizing focus, exchange and results while focusing on one of the below categories:

  • Molecular Pathogenesis, Cell Biology and Translational Research
  • Epidemiology, Staging and Prognosis
  • Diagnosis, Imaging and Biomarkers
  • Therapy & Miscellaneous
  • Clinical Trials in progress

Submit Your Research

ILCA 2020 Virtual Content is Still Available

All ILCA 2020 Virtual Conference content, along with the industry symposia, is available for up to 12 months to all registered participants on the digital platform.
Navigate through the scientific resources, presentations, Q&A sessions, e-poster presentations and more.

Download the ILCA mobile and desktop app



More Value to Your Membership

We are working on a new community tool which will offer more tailored benefits to each specific membership needs and category.

You will still get the following benefits and more!

  • Participate in ILCA educational events at a preferred rate
  • Access the latest information on liver cancer-related news and initiatives
  • Get involved in association affairs and ILCA Committees
  • Benefit from grants to support your research and enhance your career
The platform will be live soon. Stay tuned for its arrival to get your membership renewed.

Related Organisations

ILCA proudly acknowledges and thanks to the following organisations for their partnership and support in 2021.